Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + vincristine + temozolomide + anlotinib
- Development stage
- Phase 2
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This combination regimen, often referred to as IVT-A when including anlotinib, is being investigated by the Tianjin Medical University Cancer Institute and Hospital for the treatment of pediatric and adolescent patients with relapsed or refractory malignant solid tumors. The regimen combines the cytotoxic effects of liposomal irinotecan (a topoisomerase I inhibitor), vincristine (a microtubule-disrupting agent), and temozolomide (an oral alkylating agent) with the anti-angiogenic and multi-kinase inhibitory properties of anlotinib. Liposomal irinotecan provides a sustained-release formulation of the active metabolite SN-38, which inhibits DNA topoisomerase I, potentially increasing efficacy and reducing toxicity compared to standard irinotecan. Anlotinib targets VEGFR, FGFR, PDGFR, and c-Kit to inhibit tumor angiogenesis and proliferation. This multi-modal approach aims to overcome resistance in aggressive childhood cancers such as neuroblastoma and rhabdomyosarcoma.
- Other names
- IVT+A regimenIVT regimenLiposomal irinotecan-vincristine-temozolomide-anlotinib
02
Targets
DNATOP1 (DNA Topoisomerase I)FGFR (FGFR family)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on liposomal irinotecan + vincristine + temozolomide + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + vincristine + temozolomide + anlotinib.